Epidemiology of marginal zone lymphoma

Overview of attention for article published in Annals of Lymphoma, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)

Mentioned by

news: 17 news outlets
blogs: 1 blog

twitter: 6 X users
guideline: 1 clinical guideline source

Readers on

mendeley: 108 Mendeley

So far, Altmetric has seen 17 news stories from 17 outlets.

突破边界！奥布替尼获批治疗难治性边缘区淋巴瘤

CN-Healthcare, 28 Aug 2023

据小编了解，新适应症本次获批是基于一项评价奥布替尼治疗复发/难治性边缘区淋巴瘤安全性和有效性的多中心、开放性II期ICP-CL-00104研究数据。 2023年4月21日，新型BTK（布鲁顿酪氨酸激酶）抑制剂奥布替尼获得中国国家药品监督管理局（NMPA）批准…

Update on Imbruvica (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications

Drugs.com, 11 Apr 2023

HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson

Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications

Finanzen, 06 Apr 2023

HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson

Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications

Finanzen.ch, 06 Apr 2023

HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 13 additional news stories.